A computational histology artificial intelligence platform can predict which of two chemotherapy regimens is more effective for individual pancreatic cancer patients, according to a study published in the Journal of Clinical Oncology.
AIM ImmunoTech outlined key milestones for its Phase 2 DURIPANC trial evaluating Ampligen combined with durvalumab in metastatic pancreatic cancer, with primary endpoint evaluation expected in December 2026.
A UCLA clinical trial found that adding immunotherapy to chemotherapy before surgery is safe for borderline-resectable pancreatic cancer patients, with a subset experiencing deep, durable responses including complete tumor regression.
A UCLA study found that adding immunotherapy to chemotherapy before surgery is safe for borderline-resectable pancreatic cancer patients, with a subset experiencing complete tumor regression despite no overall survival advantage.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07340567 |
Personalizing Chemotherapy Selection After Surgery for Patients With Stage III Colorectal Cancer Using a Blood Test |
NOT_YET_RECRUITING | PHASE3 |
| NCT06483555 |
Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel |
RECRUITING | PHASE1/PHASE2 |
| NCT06384560 |
Neoadjuvant Triple Therapy for (Borderline) Resectable Pancreatic Cancer (PREOPANC-5) |
RECRUITING | PHASE1/PHASE2 |
| NCT06068023 |
The ADAPTA Study: ADjuvant chemotherAPy After Curative Intent resecTion of Ampullary Cancer. |
RECRUITING | |
| NCT05529940 |
NeoFOL-R Trial (Perioperative Versus Adjuvnat FOLFIRINOX in Resectable Pancreatic Cancer) |
RECRUITING | PHASE3 |
| NCT05482893 |
Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study) |
RECRUITING | PHASE1/PHASE2 |
| NCT05462496 |
Modulation of the Gut Microbiome With Pembrolizumab Following Chemotherapy in Resectable Pancreatic Cancer |
RECRUITING | PHASE2 |
| NCT05417386 |
FOLFIRINOX + NIS793 in Pancreatic Cancer |
TERMINATED | PHASE1 |
| NCT05360732 |
Redefining FOLFIORINOX in Older Pancreatic Cancer Patients |
ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT05132504 |
Neoadjuvant Folfirinox Combined With Pembrolizumab Followed by Surgery for Patients With Resectable Pancreatic Cancer |
RECRUITING | PHASE2 |
